secwatch.observer — SEC 8-K summary
======================================

Issuer:     ENANTA PHARMACEUTICALS INC (ENTA)
CIK:        0001177648
Form:       8-K
Filed at:   2026-03-26T23:59:59+00:00
Accession:  0001193125-26-125113
Event type: litigation
Sentiment:  neutral
Materiality: 0.40
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Federal Circuit schedules May 11, 2026 oral argument for Enanta's patent appeal against Pfizer over Paxlovid
--------------------------------------------------------------------------------

- Federal Circuit oral argument in Enanta's patent appeal against Pfizer (Paxlovid) set for May 11, 2026.
- Enanta originally filed suit for infringement of U.S. Patent No. 11,358,953 related to Paxlovid.
- Notice of appeal was filed on February 3, 2025.
- The appeal is before the U.S. Court of Appeals for the Federal Circuit.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1177648/000119312526125113/0001193125-26-125113-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1177648/000119312526125113/enta-20260320.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-125113

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer